 LONDON, Jan. 26, 2021 GLOBE NEWSWIRE -- Freeline Therapeutics Holdings plc Nasdaq: FRLN the Company or Freeline, a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced that it will present two e-posters at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders EAHAD taking place 3-5 February 2021. In addition, the Company will present data on its gene therapy programmes for Gaucher and Fabry Disease, in one oral platform presentation and three e-posters at the 17TH Annual WORLDSymposiumTM taking place 8-12 February 2021. 